Anti-osteoporotic treatments in neurological diseases.
The constant ageing of the population has resulted in an increase in chronic conditions such as osteoporosis and neurodegenerative diseases as well as in patient comorbidity. Prolonged immobility, the use of osteopoenia-inducing drugs and an increased risk of falls in patients with neurological diseases have led to an increase in the incidence of fragility fractures, especially of the femur, in these patients. The consequences of these events are often dramatic, being associated with increased mortality, disability and worsening of cognitive and relational functions. Potent drugs are currently available that can reduce fracture risk by up to 50% with long-term safety and tolerability. Bisphosphonates are the agents most extensively used to prevent fragility fractures. Risedronate has been demonstrated to reduce fracture risk, also in patients with neurological conditions. Considering that osteoporosis requires chronic treatment, patient compliance is extremely important to obtain treatment efficacy.
Giannini
Sandro
S
Department of Internal Medicine, University of Padua, Italy. sandro.giannini@pop.unipd.it
D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D004164:Diphosphonates / Q000627:therapeutic use*; D006801:Humans; D009422:Nervous System Diseases / Q000150:complications* / Q000188:drug therapy*; D010024:Osteoporosis / Q000209:etiology* / Q000517:prevention & control*
D050071:Bone Density Conservation Agents; D004164:Diphosphonates